Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,051 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neonatal Anemia Clear all
Completed Phase 2 Interventional Results available

Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia

NCT01005576
View directory record Official record
Conditions
Severe Thalassemia
Interventions
Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 16 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions
HQK-1001, Placebo
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Mobile, Alabama • Oakland, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

NCT01783691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NKTT120
Drug
Lead sponsor
NKT Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Sleep and Pain in Sickle Cell Disease

NCT03150433
View directory record Official record
Conditions
Sickle Cell Disease, Sleep Disturbance, Pain
Interventions
Behavioral symptom management, Sickle cell disease management
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 15, 2026, 5:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated No phase listed Observational

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

NCT04964323
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial

NCT00072761
View directory record Official record
Conditions
Sickle Cell Anemia, Stroke
Interventions
transfusion therapy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 14 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 15, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)

NCT07186179
View directory record Official record
Conditions
Diamond Blackfan Anemia
Interventions
Mobilization Regimen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated No phase listed Observational

Automated Myocardial Performance Index Using Samsung HERA W10

NCT04140669
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome, Congenital Diaphragmatic Hernia, Neural Tube Defects, Lower Urinary Tract Infection
Interventions
Automated Myocardial Performance Index (MPI)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 15, 2026, 5:45 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

NCT00962260
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

NCT02504619
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
CordIn
Biological
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Oakland, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Building Adaptive Coping and Knowledge to Improve Daily Life

NCT04602728
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Back2Life
Behavioral
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

NCT02274233
View directory record Official record
Conditions
Iron Overload, Beta-Thalassemia
Interventions
SP-420
Drug
Lead sponsor
Sideris Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 15, 2026, 5:45 PM EDT
Completed No phase listed Observational

The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria

NCT04800809
View directory record Official record
Conditions
Sickle Cell Disease, Stroke, Neurologic Manifestations, Neurological Morbidity, Sickle Cell Anemia in Children, Sickle Cell Anemia
Interventions
This study does not entail offering any intervention; all data collected will be based on standard of care.
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 26 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

NCT07402811
View directory record Official record
Conditions
Chronic Pain, Sickle Cell Disease, Sleep Disturbance
Interventions
Mobile bindfulness-based intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
15 Years to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

NCT01895998
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Albuterol
Drug
Lead sponsor
Duke University
Other
Eligibility
5 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 15, 2026, 5:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major

NCT00480506
View directory record Official record
Conditions
Thalassemia Major
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

NCT05828108
View directory record Official record
Conditions
Steroid-refractory Diamond-Blackfan Anemia (DBA)
Interventions
Bitopertin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional

AB1 in Adult Patients with Sickle Cell Disease (SCD)

NCT05261711
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
AB1
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome

NCT02122328
View directory record Official record
Conditions
Twin Twin Transfusion Syndrome
Interventions
Sequential laser photocoagulation of communicating vessels., Selective laser photocoagulation of communicating vessels
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
642 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

NCT01771731
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cannabis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 4 Interventional

Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency

NCT00243542
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ACZONE Gel, 5%, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 15, 2026, 5:45 PM EDT